Skip to content

13F-HR filed by Venrock Adviser, LLC

Venrock Adviser, LLC filed this 13F-HR for the quarter ended 2021-03-31, filed 2021-05-14, with 28 holding rows worth $921,764,000.

Accession
0001104659-21-066847
Filed
2021-05-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q1 2021

A holdings report, 28 entries on the cover page, a total value of $921,764,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $921,764,000 with VALUE read as thousands by filing date, 13F file number 028-20281. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
Instil Bio, Inc.45783C101Common Stock6,865,076$172,176,000thousands by filing date
CONSTELLATION PHARMACEUTICALS INC.210373106Common Stock4,016,873$93,955,000thousands by filing date
ACLARIS THERAPEUTICS INC COM00461U105Stock3,720,582$93,759,000thousands by filing date
OLEMA PHARMACEUTICALS INC68062P106COM1,536,193$50,971,000thousands by filing date
ALTIMMUNE INC02155H200COM NEW3,500,000$49,455,000thousands by filing date
CULLINAN THERAPEUTICS INC230031106COM1,176,145$49,010,000thousands by filing date
KINNATE BIOPHARMA INC49705R105COM1,473,014$45,899,000thousands by filing date
TRILLIUM THERAPEUTICS INC COM NEW89620X506Stock4,040,000$43,390,000thousands by filing date
MARINUS PHARMACEUTICALS INC56854Q200COM NEW2,641,809$40,895,000thousands by filing date
VISTAGEN THERAPEUTICS INC92840H202COM16,302,596$34,725,000thousands by filing date
ATHIRA PHARMA INC04746L104COM1,691,623$31,126,000thousands by filing date
RELMADA THERAPEUTICS INC75955J402COMMON STOCK853,206$30,041,000thousands by filing date
CELLDEX THERAPEUTICS INC NEW15117B202COM NEW1,240,610$25,557,000thousands by filing date
PHARVARIS NVN69605108COMMON STOCK902,882$25,335,000thousands by filing date
KEROS THERAPEUTICS INC COM492327101Stock372,306$22,915,000thousands by filing date
ESSA PHARMA INC29668H708COM NEW625,754$18,178,000thousands by filing date
KURA ONCOLOGY INC COM50127T109Stock575,000$16,255,000thousands by filing date
SYNDAX PHARMACEUTICALS INC87164F105COM591,782$13,232,000thousands by filing date
ADICET BIO INC007002108COM1,000,000$13,080,000thousands by filing date
APTOSE BIOSCIENCES INC COM03835T200Stock1,605,400$9,592,000thousands by filing date
COGENT BIOSCIENCES INC19240Q201COM1,088,817$9,560,000thousands by filing date
ALIGOS THERAPEUTICS INC COM NEW01626L105Stock408,377$9,286,000thousands by filing date
EYEPOINT INC COM NEW30233G209Stock700,000$7,112,000thousands by filing date
BCTG ACQUISITION CORP05492W103COM500,000$5,560,000thousands by filing date
METACRINE INC59101E103COM680,000$4,216,000thousands by filing date
ARS PHARMACEUTICALS INC82835W108COM85,000$3,709,000thousands by filing date
TAYSHA GENE THERAPIES INC877619106COMMON STOCK120,649$2,449,000thousands by filing date
VIRIDIAN THERAPEUTICS INC92790C104COM19,495$326,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001104659-21-066847this filing2021-05-14acceptance time not in the bulk data set